239 related articles for article (PubMed ID: 28297622)
21. Application of molecular profiling in clinical trials for advanced metastatic cancers.
Kummar S; Williams PM; Lih CJ; Polley EC; Chen AP; Rubinstein LV; Zhao Y; Simon RM; Conley BA; Doroshow JH
J Natl Cancer Inst; 2015 Apr; 107(4):. PubMed ID: 25663694
[TBL] [Abstract][Full Text] [Related]
22. Utility of adaptive strategy and adaptive design for biomarker-facilitated patient selection in pharmacogenomic or pharmacogenetic clinical development program.
Wang SJ
J Formos Med Assoc; 2008 Dec; 107(12 Suppl):19-27. PubMed ID: 19129042
[TBL] [Abstract][Full Text] [Related]
23. An integrated framework for reporting clinically relevant biomarkers from paired tumor/normal genomic and transcriptomic sequencing data in support of clinical trials in personalized medicine.
Nasser S; Kurdolgu AA; Izatt T; Aldrich J; Russell ML; Christoforides A; Tembe W; Keifer JA; Corneveaux JJ; Byron SA; Forman KM; Zuccaro C; Keats JJ; Lorusso PM; Carpten JD; Trent JM; Craig DW
Pac Symp Biocomput; 2015; ():56-67. PubMed ID: 25592568
[TBL] [Abstract][Full Text] [Related]
24. Clinical trials for predictive medicine: new challenges and paradigms.
Simon R
Clin Trials; 2010 Oct; 7(5):516-24. PubMed ID: 20338899
[TBL] [Abstract][Full Text] [Related]
25. New clinical trial designs in the era of precision medicine: An overview of definitions, strengths, weaknesses, and current use in oncology.
Janiaud P; Serghiou S; Ioannidis JPA
Cancer Treat Rev; 2019 Feb; 73():20-30. PubMed ID: 30572165
[TBL] [Abstract][Full Text] [Related]
26. An agenda for clinical trials: clinical trials in the genomic era.
Simon RM
Clin Trials; 2004; 1(5):468-70. PubMed ID: 16279285
[No Abstract] [Full Text] [Related]
27. State of the art discovery with tumor profiling in pediatric oncology.
Carroll WL; Raetz E; Meyer J
Am Soc Clin Oncol Educ Book; 2015; ():e601-7. PubMed ID: 25993229
[TBL] [Abstract][Full Text] [Related]
28. The clinical trial landscape in oncology and connectivity of somatic mutational profiles to targeted therapies.
Patterson SE; Liu R; Statz CM; Durkin D; Lakshminarayana A; Mockus SM
Hum Genomics; 2016 Jan; 10():4. PubMed ID: 26772741
[TBL] [Abstract][Full Text] [Related]
29. The project data sphere initiative: accelerating cancer research by sharing data.
Green AK; Reeder-Hayes KE; Corty RW; Basch E; Milowsky MI; Dusetzina SB; Bennett AV; Wood WA
Oncologist; 2015 May; 20(5):464-e20. PubMed ID: 25876994
[TBL] [Abstract][Full Text] [Related]
30. Reinventing clinical trials: a review of innovative biomarker trial designs in cancer therapies.
Lin JA; He P
Br Med Bull; 2015 Jun; 114(1):17-27. PubMed ID: 25921239
[TBL] [Abstract][Full Text] [Related]
31. Future of clinical genomics in pediatric oncology.
Janeway KA; Place AE; Kieran MW; Harris MH
J Clin Oncol; 2013 May; 31(15):1893-903. PubMed ID: 23589558
[TBL] [Abstract][Full Text] [Related]
32. NCCN Working Group report: designing clinical trials in the era of multiple biomarkers and targeted therapies.
Venook AP; Arcila ME; Benson AB; Berry DA; Camidge DR; Carlson RW; Choueiri TK; Guild V; Kalemkerian GP; Kurzrock R; Lovly CM; McKee AE; Morgan RJ; Olszanski AJ; Redman MW; Stearns V; McClure J; Birkeland ML
J Natl Compr Canc Netw; 2014 Nov; 12(11):1629-49. PubMed ID: 25361808
[TBL] [Abstract][Full Text] [Related]
33. Experience with precision genomics and tumor board, indicates frequent target identification, but barriers to delivery.
Bryce AH; Egan JB; Borad MJ; Stewart AK; Nowakowski GS; Chanan-Khan A; Patnaik MM; Ansell SM; Banck MS; Robinson SI; Mansfield AS; Klee EW; Oliver GR; McCormick JB; Huneke NE; Tagtow CM; Jenkins RB; Rumilla KM; Kerr SE; Kocher JA; Beck SA; Fernandez-Zapico ME; Farrugia G; Lazaridis KN; McWilliams RR
Oncotarget; 2017 Apr; 8(16):27145-27154. PubMed ID: 28423702
[TBL] [Abstract][Full Text] [Related]
34. Molecular Screening for Cancer Treatment Optimization (MOSCATO-01) in Pediatric Patients: A Single-Institutional Prospective Molecular Stratification Trial.
Harttrampf AC; Lacroix L; Deloger M; Deschamps F; Puget S; Auger N; Vielh P; Varlet P; Balogh Z; Abbou S; Allorant A; Valteau-Couanet D; Sarnacki S; Gamiche-Rolland L; Meurice G; Minard-Colin V; Grill J; Brugieres L; Dufour C; Gaspar N; Michiels S; Vassal G; Soria JC; Geoerger B
Clin Cancer Res; 2017 Oct; 23(20):6101-6112. PubMed ID: 28733441
[No Abstract] [Full Text] [Related]
35. Defining precision: The precision medicine initiative trials NCI-MPACT and NCI-MATCH.
Coyne GO; Takebe N; Chen AP
Curr Probl Cancer; 2017; 41(3):182-193. PubMed ID: 28372823
[TBL] [Abstract][Full Text] [Related]
36. Omics-based clinical trial designs.
Buyse M; Michiels S
Curr Opin Oncol; 2013 May; 25(3):289-95. PubMed ID: 23475192
[TBL] [Abstract][Full Text] [Related]
37. Clinical trial designs incorporating predictive biomarkers.
Renfro LA; Mallick H; An MW; Sargent DJ; Mandrekar SJ
Cancer Treat Rev; 2016 Feb; 43():74-82. PubMed ID: 26827695
[TBL] [Abstract][Full Text] [Related]
38. Genomic Alteration-Driven Clinical Trial Designs in Oncology.
Simon R
Ann Intern Med; 2016 Aug; 165(4):270-8. PubMed ID: 27214515
[TBL] [Abstract][Full Text] [Related]
39. Genomic medicine frontier in human solid tumors: prospects and challenges.
Dienstmann R; Rodon J; Barretina J; Tabernero J
J Clin Oncol; 2013 May; 31(15):1874-84. PubMed ID: 23589551
[TBL] [Abstract][Full Text] [Related]
40. A Multidisciplinary Evaluation of Barriers to Enrolling Cancer Patients into Early Phase Clinical Trials: Challenges and Patient-centric Recommendations.
Babiker HM; Davis L; Larson K; Placencia C; Swensen C; Tenneti P; Lim M; Cañamar R; Curtis J; Castillo E; Mancuso J; Rensvold D; Martinez S; Macias L; Recio-Boiles A; Chandana SR; Mahadevan D
Expert Opin Investig Drugs; 2019 Aug; 28(8):675-686. PubMed ID: 31327293
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
